TX-FLUENCE
2.2.2023 14:31:43 CET | Business Wire | Press release
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, is supporting widespread expansion of pharmaceutical-grade medical cannabis cultivation operations in Portugal.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230202005215/en/
Fluence LEDs in action at the Key Leaves facility in Portugal (Photo: Business Wire)
Portugal’s cannabis laws are among the most progressive in the world, and its established licensing system is ahead of most other European countries. Portugal decriminalized personal cannabis use in 2001 and legalized medical use in 2018. Since then, 20 official licenses for medical cannabis production, processing, import, export or a combination of categories have been issued, and Fluence has been chosen to provide lighting for over half of them.
Key Leaves, a medical cannabis market leader in Portugal, is one of the 20 companies to have received a medical cannabis license from the Portuguese government. The company is focused on delivering premium quality medicinal cannabis products that adhere to the Good Agricultural and Collection Practice (GACP) and Good Distribution Practices (GDP) wholesale standards, along with all relevant Portuguese regulations.
As a fully indoor facility dedicated to research and development, Key Leaves depends on sole-source lighting for its success—completing more than 20 full cultivation cycles using Fluence LED technology. Fluence’s LEDs have helped Key Leaves optimize production and cultivation light cycles, increase plant yield, uniformity and decrease energy consumption.
“To achieve our business objectives using the most effective and efficient production processes possible, we’ve invested in the world-class technologies and partnerships available,” said Alessandro Radici, CEO at Key Leaves. “Fluence’s market-leading LED technology and the on-call support of its research and horticulture teams allow us to cultivate with maximum efficacy, deliver a highly standardized product and guarantee constant supply for our clients.”
Fluence provides LED lighting solutions to 10 other licensed Portuguese medical cannabis producers—including Bathera, Curaleaf International and Clever Leaves, and pre-licensed AceCann—as well as several additional companies that are currently seeking licensing. Bathera, a German company, recently began producing its own medical cannabis and decided to construct its indoor cultivation and manufacturing facility near Lisbon. The site, currently in progress, houses 6,000 square meters of rooms dedicated to cultivation and 3,000 square meters of space for supporting areas, such as a GMP zone, six drying rooms and space for hand trimming and manual packaging.
“Because of the great Portuguese weather, outdoor cultivation is, of course, possible. We performed rigorous research and analysis with every construction decision and, after looking at the various options, we decided that cultivating indoors is the only way to ensure stable, high-quality products,” said Boris Agababov, founder and CEO of Bathera.
Curaleaf International focuses on advancing the therapeutic value of cannabis used for medicinal purposes to develop products that meet the needs of patients across Europe. The company’s commitment to accessibility, research and data-led product excellence brought it to Fluence when a lighting partner was needed for its Portuguese operations.
“Fluence’s goal is to help our customers grow smarter and build efficient economies of scale,” said Jörg Meyer-Brenken, lead account manager of cannabis in EMEA at Fluence. “We are led by science, and the collaborative approach we take to provide our partners with tailored lighting solutions, knowledge and experience has proven irreplaceable, especially for those in emerging medicinal cannabis markets.”
Portuguese native André Lagareiro, Fluence’s dedicated account manager for Portugal, works closely with Fluence’s Portuguese customers to help them identify the right lighting solutions to optimize plant growth and facility operations.
“Helping companies to innovate and advance medical cannabis operations within Portugal’s legislative environment requires a deep understanding of both cannabis cultivation and European regulatory standards,” said Lagareiro. “The unmatched top-of-the-line product, market expertise and quality of service provided by Fluence’s in-house research and development team is the deciding factor for the many Portuguese cannabis companies that have chosen Fluence as their lighting technology partner.”
For more information on Fluence, visit www.fluence.science.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
About AceCann
AceCann is a Portuguese medical cannabis company that has a cost-efficient, scalable and superior quality organic indoor cultivation and extraction facility near Lisbon. AceCann is focused on the development of new medical delivery forms for cannabis, joining efforts with local and international universities and operating on a flexible structure capable of making fast decisions to scale according to market demands and needs.
About Key Leaves
Key Leaves is a Portuguese-founded company established in 2015 and licensed by Infarmed for the cultivation, import and export of cannabis products. With a multicultural and diversified international team, Key Leaves is proud to be working with some of the most renowned professionals and experts in the medicinal cannabis field.
About Bathera
Bathera is a vertically integrated medical cannabis company with operations in Germany and Portugal. In addition to its state of the art indoor medical cannabis growing facility in Portugal, Bathera, operates two independent wholesalers and importers for medical cannabis in Germany.
About Curaleaf
Curaleaf International (formerly EMMAC Life Sciences Group) is Europe’s largest vertically integrated cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, Curaleaf International’s vision is to bring the life-enhancing potential of cannabis to the people who need it. EMMAC Life Sciences was acquired by Curaleaf Holdings in March 2021. For more information about Curaleaf International, please visit www.curaleafinternational.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230202005215/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom